Thomas Busby Promoted to Director at Outcome Capital

Outcome Capital has promoted Thomas F. Busby to director at its Boston office. Formerly a senior vice president, Busby will now focus on the medical device, digital health, and life science services verticals within Outcome’s strategy-driven platform, providing M&A, capital raising and advisory services to clients.
 
“The climate is right for life science dealmaking as we head into 2024, and Thom’s experience, expertise and integrity have long been lauded by our clients. Thom’s promotion will directly benefit Outcome’s clients and is in-line with our continued commitment to the advancement of life science technologies, as well as our teams’ professional development,” Co-Founders and Managing Partners Dr. Oded Ben-Joseph and Arnold Freedman said.
 
Busby joined Outcome Capital in 2015 and has advised dozens of management teams throughout the life sciences spectrum. Having advised on biopharma, medical device, diagnostics, laboratory, healthcare IT, and outsourced services mandates, Busby’s clients benefit from the breadth of his experience and his deep sector knowledge. During his time with Outcome Capital, Busby supervised numerous private equity and debt placements, in addition to executing various strategic M&A transactions with both public and private buyers and sellers.
 
“Beyond knowing the market and our technology as well as anyone, Thom’s authenticity and calm, yet relentless, focus makes him unique. He is someone you want to have in your corner, advocating and advising on your and your shareholders’ behalf,” ntoed Chris Mathia, former Innara Health CEO and former client of Busby’s.
 
Outside of Busby’s transactional work, he is a board member of HealthTech Build, a Boston-based digital health trade group, and a frequently published author in medical device and life science trade journals. He earned both an MBA and bachelor of science degree from Suffolk University and previously worked in the non-profit and philanthropic sectors.
 
“First and foremost, I am excited to continue to serve and work with our industry’s founders and innovators to provide strategic and financial advice. It has been my pleasure to grow alongside Outcome Capital, and in this new role I look forward to continuing this trajectory,” Busby stated.
 
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing companies with a value-added, market-aligned approach to mergers and acquisitions, partnering, and corporate finance. The firm leverages its ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.